# Safety Study of GPX-150 in Patients With Solid Tumors

> **NCT00710125** · PHASE1 · COMPLETED · sponsor: **Gem Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Advanced Solid Tumors - Phase 1 Population

## Interventions

- **DRUG:** GPX-150 for Injection

## Key facts

- **NCT ID:** NCT00710125
- **Lead sponsor:** Gem Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00710125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00710125, "Safety Study of GPX-150 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00710125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*